Exemestane API Market Size Was Valued at USD 1.19 Billion in 2023, and is Projected to Reach USD 2.03 Billion by 2032, Growing at a CAGR of 6.1 % From 2024-2032. Exemestane API, additionally referred to as Aromasin, actively inhibits estrogen synthesis in postmenopausal ladies, playing a crucial position in treating estrogen receptor-positive breast cancer. It is characterised with the...